Safety Considerations in Retinal Vascular Diseases

In this episode, “Safety Considerations in Retinal Vascular Diseases,” the panelists explore practical approaches to monitoring and managing safety considerations associated with anti-VEGF therapy in retinal vascular diseases. The expert faculty discuss how treatment frequency, injection volume, and preexisting ocular conditions may influence clinical decision-making when treating patients with wet AMD, diabetic macular edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO).

Throughout the discussion, the panel highlights the importance of minimizing treatment burden while also recognizing that every intravitreal injection carries procedural risks, including infection, retinal detachment, bleeding, and transient intraocular pressure (IOP) elevation. The expert faculty discuss how newer higher-volume therapies, such as aflibercept 8 mg, may require additional consideration in patients with glaucoma, optic neuropathy, or advanced cupping. In addition, the panel reviews practical strategies used in clinical practice to reduce transient IOP spikes and improve patient comfort, including prophylactic IOP-lowering drops, ocular softening techniques, and anterior chamber paracentesis in select high-risk patients.

The panel also explores the balance between injection volume and long-term treatment frequency, noting that fewer injections over time may potentially reduce cumulative stress on the optic nerve despite slightly higher injection volumes with some therapies. The expert faculty emphasize the importance of individualized patient management and patient education, particularly regarding expected visual symptoms immediately following injection. Overall, the discussion highlights how safety monitoring and procedural optimization remain essential components of long-term anti-VEGF therapy management across retinal vascular diseases.

The next episode in this series, “Port Delivery System Therapies in Retinal Vascular Diseases,” features the panelists discussing how the ranibizumab port delivery system fits into the evolving treatment landscape for retinal vascular diseases. The expert faculty also highlight durability benefits, safety considerations, patient selection, and how newer long-acting anti-VEGF therapies may influence adoption of surgical delivery approaches.